Study ID: C38072/3085 | 2010-024540-15

Study Title

Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma

Teva Identifier

C38072/3085 | 2010-024540-15

ClinicalTrials.gov Identifier

NCT01290887

Study Status

Terminated

Trial Condition(s)

Eosinophilic Asthma

Interventions

Drug: Reslizumab

Study Description

Please refer to ClinicalTrials.gov for a description of the trial

Key Participation Requirements

Gender

Female, Male

Age Range

12 Years to 75 Years

Trial Duration

06/01/2011 - 01/01/2015

Phase

Phase 3

Study Type

Interventional